

**DATA SHEET**  
**Hsa-miR-342-3p fluoresceinated oligo probe**

**Catalog No.**  
**HM342-3p-100**

**Description**  
One vial of 0.650 ml of probe in hybridization buffer

**Analyte Specific Reagent. Analytical and performance characteristics are not established.**

---

Doc. No. 932-HM342-3p-100

Rev. C

Date of release: 25-Jul-2024

**Description**

The Hsa-miR-342-3p probe has been designed from mature human miR-342-3p sequence. This fluoresceinated probe is provided in a hybridization buffer for localization of miRNA in FFPE tissue by *In Situ* hybridization.

**Specifications**

The Hsa-miR-342-3p identifies mature miR-342-3p sequences in formalin-fixed, paraffin-embedded human tissues and/or freshly prepared frozen tissues by *in situ* hybridization. This probe does not react with normal human mRNA or nuclear DNA present in tissues.

**Storage and Handling**

Store the reagent at 2-8 °C. Do not freeze. Do not use the reagent after expiration date on vial. The reagent must be brought to room temperature before use. (Important! The presence of precipitates induces background staining).

**Precautions:**

For professional use the probe contains formamide. Formamide is classified as a teratogen. Pregnant workers should keep exposure to a minimum. Avoid inhalation, ingestion, and contact with unprotected skin. If skin contact occurs, wash thoroughly with soap and water. For more information, refer to the Material Safety Data Sheet, which is available upon request.

**Quality Control**

Each lot of this micro RNA probe is tested by *In Situ* hybridization for Quality Control purposes. Refer to the BioGenex Quality Control Testing Conditions table for additional information.

**References**

1. Li XR, Chu HJ, Lv T, Wang L, Kong SF, Dai SZ. (2014) miR-342-3p suppresses proliferation, migration and invasion by targeting FOXM1 in human cervical cancer. *FEBS Lett.* 2014 Aug 25;588(17):3298-307
2. Fourie NH, Peace RM, Abey SK, Sherwin LB, Rahim-Williams B, Smyser PA, Wiley JW, Henderson WA. (2014) Elevated circulating miR-150 and miR-342-3p in patients with irritable bowel syndrome. *Exp Mol Pathol.* 2014 Jun;96(3):422-5.
3. Xie X, Liu H, Wang M, Ding F, Xiao H, Hu F, Hu R, Mei J. miR-342-3p targets RAP2B to suppress proliferation and invasion of non-small cell lung cancer cells. *Tumour Biol.* 2015 Jul;36(7):5031-8.

**BioGenex Quality Control Testing Conditions**

<b>Parameter</b>	<b>Conditions used</b>
Control Tissue	Testis (FB-HM342-3p)
Tissue Type	Formalin-fixed, paraffin-embedded cancer tissues